Spike glycoprotein, Spike S1 subunit, S glycoprotein, CR3022

SARS-CoV-2

CPC520B pdf (datasheet)

100 µg

Please Inquire

1.0 mg/ml

New catalog number RVV00303

CR3022, which was previously isolated from a convalescent SARS-CoV–infected patient, is a neutralizing antibody obtained in complex with the receptor-binding domain of the SARS-CoV-2 spike. The antibody binds to an epitope conserved between SARS-CoV-2 and SARS-CoV that is distinct from the receptor-binding site. CR3022 was shown to neutralize SARS-COV in a concerted action with clone CR3014. Presence of both antibodies delivers a blocking action of the SARS-COV RBD-ACE2 interaction, by binding two distinct and functional epitopes.

Spike glycoprotein

P0DTC2

Reacts with aa 318-510 in the S1 domain of the SARS-CoV and CoV-2 Spike protein. Binds to P462L-substituted S318–510 fragments of the SARS spike protein. The binding epitope is only accessible in the "open" conformation of the spike protein.

Human

Isolated from a convalescent SARS-CoV–infected patient

IgG1

CR3022

Sterile-filtered PBS, pH 7.5 preservative free.

Protein A affinity chromatography

ELISA, FS , Neutralizing , WB

ELISA: 1:5,000 - 1:10,000
Western blot: suggested dilution 1:1,000 - 1:2,000

Stable at 2-8°C for 1 week or for up to 1 year at -20°C to -80°C. It is recommended to prepare working aliquots of undiluted product and store -20°C to -80°C.